Key laboratory for Cell Proliferation and Regulation Biology Ministry of Education; Universities' Confederated Institute of Proteomics, Beijing, China.
Eur J Cancer Care (Engl). 2009 Nov;18(6):625-35. doi: 10.1111/j.1365-2354.2008.00965.x. Epub 2009 May 28.
Serum samples from 60 cholangiocarcinoma (CC), 60 benign diseases of hepatobiliary and 53 normal individuals were analysed by SELDI-TOF-MS (Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry). It was found that a 28 k m/z peak was significantly decreased in CC and retained discriminatory value between CC and normal group, also between CC and benign groups. Then 1-D, 2-D gel electrophoresis and tandem mass spectroscopy were employed to isolate and identify the protein that correlates with observed SELDI-TOF-MS (m/z) value. The results demonstrated that 28 k m/z peak was apolipoprotein A-I (ApoA-I) and its identity was further validated by immunodepletion and Western blotting analysis. Subsequently, it was inspiring found that the decreased level of ApoA-I analysed by enzyme linked immunosorbent assay was consistent with SELDI-TOF-MS analysis. Therefore, it suggested that ApoA-I could be a potential useful biomarker for CC.
采用表面增强激光解吸/电离飞行时间质谱（SELDI-TOF-MS）技术分析了 60 例胆管癌（CC）、60 例肝胆良性疾病和 53 例正常人的血清样本。结果发现，CC 患者血清中 28kDa 峰明显降低，且在 CC 与正常组、CC 与良性组之间仍具有鉴别价值。然后采用一维、二维凝胶电泳和串联质谱技术分离和鉴定与观察到的 SELDI-TOF-MS（m/z）值相关的蛋白质。结果表明，28kDa 峰为载脂蛋白 A-I（ApoA-I），通过免疫沉淀和 Western blot 分析进一步验证了其身份。随后，令人鼓舞的是，酶联免疫吸附试验分析的 ApoA-I 水平降低与 SELDI-TOF-MS 分析一致。因此，提示 ApoA-I 可能是 CC 的潜在有用生物标志物。
